Future prospects of Qiliqiangxin on heart failure: epigenetic regulation of regeneration

and Drug Administration for the treat-ment of heart failure in 2004 (Li et al., 2013). Our recent multicenter, ran-domized, double-blind, parallel-group, placebo-controlled study of the effects of QL capsules in patients with chronic heart failure shows that on a background of standard treatment, QL capsules further decreases the levels of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) during 12 weeks of treatment (Li et al., 2013). However, the underlying mechanism is still unclear. Recent progress in studying QL on improving exercise tolerance and patients